Bifogade filer
Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Initiator Pharma via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
2023-02-17 08:30:00
Business highlights in Q4 2022
- On October 4th the Company announced the outcome of the incentive program ‘LTI2022’ approved by the AGM on May 24th 2022.
- On November 4th the Company provided an update on its clinical programs.
- On December 20th the Company started a Phase 1 pharmacokinetics study for new IP2015 formulations.
- On December 23rd the Company announced that it had decided not to exercise the option for an undisclosed pain asset.
Business highlights after this reporting period
- Nothing to report.
Financial Highlights
Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK).
Fourth Quarter (2022-10-01 – 2022-12-31) |
Net revenue were TDKK 0 (0) |
Operating loss, EBIT was TDKK -6,477 (-7,280) |
Earnings per share was DKK –0.06 (-0.11) |
Cash: TDKK 39,112 (34,346) |
Solidity: 72% (92%) |
Full Year (2022-01-01 – 2022-12-31) |
Net revenues were TDKK 0 (0) |
Operating loss, EBIT was TDKK -41,740 (-23,072) |
Earnings per share was DKK –0.73 (-0.60) |
As disclosed in the Q1:2022 report Initiator Pharma publishes its interim reports in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/